請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38043
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 劉順仁 | |
dc.contributor.author | Chi-Liang Chen | en |
dc.contributor.author | 陳計良 | zh_TW |
dc.date.accessioned | 2021-06-13T15:58:23Z | - |
dc.date.available | 2008-06-05 | |
dc.date.copyright | 2008-06-05 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-05-27 | |
dc.identifier.citation | Abbott, T. A., and Vernon, J. A. (2005). The cost of US pharmaceutical price reductions: A financial simulation model of R&D decisions: National Bureau of Economic Research, Inc.
Andersson, K., Bergström, G., Petzold, M..G., and Carlsten, A. (2007). Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals. Health Policy, 81, 376-384. Bloor, K., and Freemantle, N. (1996). Lessons from international experience in controlling pharmaceutical expenditure. II: Influencing doctors. British Medical Journal, 312(7048), 1525-1527. Bloor, K., Maynard, A., and Freemantle, N. (1996). Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry. British Medical Journal, 313(7048), 33-35. Bureau of National Health Insurance. (2007a). An exploration of the drug reimbursement system. [http://www.nhi.gov.tw/webdata/AttachFiles/Attach_9151_2_%A7%DA%B0%EA%C3%C4%AB~%A4%E4%A5I%A8%EE%AB%D7%B1%B4%B0Q%BA[%B0%EA%BB%DA%A4%F1%B8%FB960309.pdf] Bureau of National Health Insurance. (2007b). General principles. [http://www.nhi.gov.tw/webdata/AttachFiles/Attach_8556_2_chi65-1.pdf] Bureau of National Health Insurance. (2007c). Guidelines of price adjustment for National Health Insurance reimbursed drugs. [http://www.nhi.gov.tw/webdata/AttachFiles/Attach_8559_2_chi65-4.pdf] Bureau of National Health Insurance. (2007d). Principles on drug reimbursement price approval of National Health Insurance. [http://www.nhi.gov.tw/webdata/AttachFiles/Attach_8558_2_chi65-3.pdf] Cabiedes, L., and Ortun, V. (2005). Prescriber incentives. The Public Financing of Pharmaceuticals: An Economic Approach, Puig-Junoy J (ed). Edward Elgar, 167-186. Chou, Y. J., Yip, W. C., Lee, C., Huang, N., Sun, Y., and Chang, H. (2003). Impact of separating drug prescribing and dispensing on provider behavior: Taiwan’s experience. Health Policy and Planning, 18(3), 316-329. Cromwell, D. M., Bass, E. B., Steinberg, E. P.,Yashi, Y., Ravich, W. J., Hendrix, T. R., McLeod, S. F., and Moore, R. D. (1999). Can restrictions on reimbursement for anti-ulcer drugs decrease Medicaid pharmacy costs without increasing hospitalizations? Health Services Research, 33(6), 1593-1610. Ess, S. M., Schneeweiss, S., and Szucs, T. D. (2003). European healthcare policies for controlling drug expenditure. Pharmacoeconomics, 21(2), 89-103. Towse, A., and Garrison, L. (2003). The drug budget silo mentality in Europe: an overview. Value inHhealth 2003, 6 Suppl 1, 1-9. Gerdtham, U., Johannesson, M., Gunnarsson, B., Marcusson, M., and Henriksson, F. (1998), The effect of changes in treatment patterns on drug expenditure. Pharmacoeconomics, 13(1 pt 2), 127-134. Gerdtham, U., and Lundin, D. (2004), Why did drugs spending increase during the 1990s? Pharmacoeconomics, 22(1), 29-42. Giuliani, G., Selke, G., and Garattini, L. (1998). The German experience in reference pricing. Health Policy, 44, 73-85. Grootendorst, P., and Stewart, D. (2006). A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia. Health Economics, 15, 735-742. Guillen, A. M., and Cabiedes, L. (2003). Reforming pharmaceutical policies in the European Union: a 'penguin effect'? International Journal of Health Services, 33(1), 1-28. Hemenway, D., A. Killen, S. B. Cashman, C. L. Parks, and W. J. Bicknell (1990). Physicians’ response to financial incentives- evidence from a for- profit ambulatory care center. The New England Journal of Medicine, 322, 1059-1063. Kreft, I., and de Leeuw, J. (1998). Introducing multilevel modeling, Sage Publications of London Johnson, R. E., Goodman, M. J., Hornbrook, M.C., and Eldredge, M. B. (1997). The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs received and on the health status of elderly HMO members. Health Services Research, 32(1), 103-122. Kaló, Z., Muszbek, N., Bodrogi, J., and Bidló, J. (2007). Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Health Policy , 80, 402-412. Lee, Y. C., Yang, M. C., Huang, Y. T., Liu, C. H., and Chen, S. B. (2006). Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003. Pharmacoeconomics, 24(9): 891-902 Lichtenberg, F. R. (2001). The benefits and costs of newer drugs: Evidence from the 1996 Medical expenditure panel survey: National Bureau of Economic Research, Inc. Liu, S. Z., and Romies, J. C. (2003). Assessing the effect of Taiwan’s outpatient prescription drug copayment policy in the elderly, Medical Care, 41(12), 1331-1342. Liu, S. Z., and Romies, J. C. (2004). Changes in drug utilization following the outpatient prescription drug cost-sharing program –Evidence from Taiwan’s elderly, Health Policy, 68, 277-287 Mensah, Y. M. (2000), Accounting issues in health care, Journal of Accounting and Public Policy, 19, 3-7. Morgan, S. G., and Agnew, J. D. (2004). Barer ML: Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia. Health Policy, 68, 299-307. Mossialos, E., and Oliver, A. (2005). An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. International Journal of Health Planning and Management. 20, 291-306. Porter, M. E., and Teisberg, E. O. (2006). Redefining health care: Creating value-based competition on results. Harvard Business School press. Puig-Junoy, J. (2004). Incentives and pharmaceutical reimbursement reforms in Spain. Health Policy, 67, 149-165. Puig-Junoy, J. (2005). Price regulation systems in the pharmaceutical market. The public financing of pharmaceuticals: An economic approach, Puig-Junoy J (ed). Edward Elgar, 35-58. Scherer, F. M. (2000). The pharmaceutical industry. Handbook of Health Economics, volume 1, Culyer AJ, Newhouse JP (eds). Elsevier Science: New York, 1297-1336. Schweitzer, S. O. (1997). Pharmaceutical economics and policy. Oxford University Press. Sims, P. D., Daley, C. W., and Alfano, L. (1984). The incentive plan- an approach for modification of physician behavior. American Journal of Public Health, 74, 150-152. Street, A., Jones, A., and Furuta, A. (1999). Cost-sharing and pharmaceutical utilisation and expenditure in Russia. Journal of Health Economics, 18(4), 459-472. Taiwan Department of Health. (2004). Overview of the national health insurance reform. Taiwan Department of Health. Wilson, T. W., Chockalingam, A., and Quest, D. W. (1996). Pharmacoeconomics of hypertension control: basic principles of economic evaluation. Journal of Human Hypertension, 10(2), S19-22. Yip, W. (1998), Physician response to Medicare fee reductions: changes in the volume of coronary artery bypass graft (CABG) surgeries in the Medicare and private sectors. Journal of Health Economics, 17(6), 675-699. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38043 | - |
dc.description.abstract | 逐年上漲的醫療支出已經成為各國政府所面臨的嚴重問題,而且急需尋求解決的對策。其中藥品費用上漲的速度更超過整體醫療支出上升的速度,這促使許多控制藥品費用的政策被制訂以抑制藥品費用的上漲。台灣實施「全民健康保險」制度已超過十年,在控制藥品費用上也實施了許多政策,其中藥價給付費率調降政策在2000年至2003年更是執行了三次,每一次藥價調降的幅度及種類項目均不相同,究竟其成效如何以及對藥品使用療效之潛在影響,還有不同醫院對此政策之反應,實是值得加以進行系統性之研究。
本文擷取全民健康保險研究資料庫之歸人檔承保資料,去除藥價給付費率調降政策以外的其他政策影響以及考慮季節效果之後,挑選出40歲以上之高血壓病人樣本族群,三次調降政策分別為5698人、5862人以及6432人,另外,依照世界衛生組織之「藥品解剖學治療學化學分類系統」,再從這些樣本族群的門診資料彙整出最常用的兩類高血壓藥物,採用階層線性模型來分析醫療服務供給者在面臨藥價給付費率調降政策的負面財務誘因時,其醫療行為的改變對此政策控制藥品價格的效果以及對藥品使用療效之影響。 本文研究結果發現,在2000年至2003年執行的三次藥價調降政策,對於兩類最常用的高血壓藥物並不具有價格控制效果,亦即想藉由控制藥品價格來降低藥品支出的政策目標並無法達成;另外,在相同的藥品成本下,也無法增進藥品使用的療效。根據階層線性模型的分析結果,發現不同特質及屬性的醫院對藥價調降政策確實具有不同的反應。 | zh_TW |
dc.description.abstract | Rapidly rising pharmaceutical costs have been a worldwide problem. Under such pressure, governments in many countries have launched various programs in order to curtail the growth of drug expenditure; among them, drug price control is frequently used. Extant research, however, has used macro-level (aggregate) data and can only provide very limited insights into the effect of the drug price control policy on health care providers’ prescription behaviors. Consequently, these works fall short in examining whether the pharmaceutical price control policy can improve the cost-curative effect of pharmaceutical use, and whether the drug price control policy may have different influences on health care providers with different characteristics.
This study investigates influences of Taiwan’s drug reimbursement rate reduction policy in its National Health Insurance system on the price level and the cost-curative effect of pharmaceutical use, using hypertension patients’ usage of hypotensive agents as the example for such analysis. Specifically, we take advantage of the rich content of data in the National Health Insurance Research Database to construct a micro-level database that enables us to examine the following additional two issues: (1) whether the pharmaceutical price control policy has helped improve the cost-curative effect of usage of hypotensive agents, and (2) whether this policy has different effects on health care providers with different characteristics. We used Taiwanese hypertension patients aged 40 or over as our study population. This population accounts for almost the entire population of hypertension patients who take prescription drugs. We selected the two most used narrow classes of hypotensive agents based on the first four digits of the coding system of Anatomical Therapeutic Classification (ATC). They are peripherally acting antiadrenergic agents (ATC code=C02C) and plain angiotensin II antagonists (ATC code=C09C).To provide insights into whether the reimbursement rate reduction policy has had different effects for hospitals with different characteristics, we apply the hierarchical linear modeling (HLM) technique. Findings from this study indicate that the price control initiatives between 2000 and 2003 were not helpful for improving the cost-curative effect of using the C02C and the C09C drugs, since the daily expense was not reduced for these two drug classes because of the initiatives. As the magnitude of price reduction level was small for each of the two drug classes, such findings reflect the uselessness of the small price reduction. While the drug price control policy had insignificant effects on the daily expense for the C02C drugs and the C09C drugs, variations in the influence existed among health care providers with different characteristics. Physicians in public hospitals appeared to prescribe cheaper C09C drugs after the 2000 price reduction. In contrast, physicians in medical centers tended to prescribe more expensive drugs in the two classes after a reimbursement rate reduction action. The percentage of the specialist group comprising cardiologists, nephrologists, and internal medicine physicians in a hospital was associated with a tendency to prescribe more expensive C09C drugs after the 2001 and the 2003 reductions. The different changes in the daily expense after the drug price reductions for hospitals suggest that hospitals with different characteristics might have different patterns of switching drug types in their prescriptions or some patients might switch hospitals after an action of reimbursement rate reduction. Such results suggest a need for the government to better monitor health providers’ behavior of switching prescription drugs and patients’ behavior of switching hospitals so as to have a better understanding with respect to how drug price control actions could affect pharmaceutical expenditures and health care quality. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T15:58:23Z (GMT). No. of bitstreams: 1 ntu-97-D90722002-1.pdf: 467923 bytes, checksum: 87e7893f903cf54dffe752c563f132c4 (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 1 INTRODUCTION 1
2 BACKGROUND OF TAIWAN’S PRESCRIPTION DRUG REIMBURSEMENT RATE REDUCTION POLICY 7 3 LITERATURE REVIEW 14 3.1 Price Regulation and Prescriber Incentive Policies, and Their Effects on Drug Expenditure 14 3.2 The Effects of Taiwan’s Health Polices for Controlling the Growth of Drug Expenditure 18 4 CONCEPTUAL FRAMEWORK and RESEARCH METHODOLOGY 22 4.1 Conceptual Framework 22 4.2 Study Design 24 4.2.1 Study objectives 24 4.2.2 Selection of study periods and populations 25 4.2.3 Unit of analysis 27 4.3 Data Sources 27 4.4 Statistical Model and Empirical Specification 30 5 EMPIRICAL RESULTS 37 5.1 Sample Characteristics 37 5.2 The Influences on Price Control and Cost-curative effect of Drug Reimbursement Rate Reduction Policy 39 5.3 The Influences of the Other Micro-Level Explanatory Variables 40 5.4 The Relationship of the Price Control Effect of Reimbursement Rate Reduction with the Macro-Level Explanatory Variables --- Hospital Features 40 5.5 Fitness and Robustness for the Results 42 5.5.1 The fitness of HLM RC model 42 5.5.2 The sensitivity of results from estimation based on different criteria for selecting macro-level units as study subjects 43 6 DISCUSSION and CONCLUSIONS 45 6.1 Policy Implications 45 6.2 Research Limitations 49 6.3 Future Research Directions 51 6.4 Conclusions 52 REFERENCES 54 | |
dc.language.iso | en | |
dc.title | 台灣全民健康保險藥價給付費率調降政策在價格管控之影響的探討--- 以降血壓藥為例之實證研究 | zh_TW |
dc.title | Exploration of the Influences on Price Control of Drug Reimbursement Rate Reduction Policy in Taiwan’s National Health Insurance System--- An Empirical Study on Hypotensive Agents | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 王泰昌,劉啟群,周穎政,鄭守夏 | |
dc.subject.keyword | 成本控制政策,藥品支出,財務誘因,醫療提供者行為,全民健康保險, | zh_TW |
dc.subject.keyword | Cost control policy,Drug expenditure,Financial incentive,Health care providers’ behavior,National Health Insurance system, | en |
dc.relation.page | 87 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-05-28 | |
dc.contributor.author-college | 管理學院 | zh_TW |
dc.contributor.author-dept | 會計學研究所 | zh_TW |
顯示於系所單位: | 會計學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 456.96 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。